Aktis Oncology is pioneering advancements in cancer treatment through the development of precision radiopharmaceuticals that utilize alpha-emitting particles. These targeted therapies are designed to effectively destroy cancer cells while minimizing damage to healthy tissues. By focusing on a wide range of targets associated with common cancers, Aktis aims to provide innovative solutions for tumors that currently have limited treatment options. Their approach emphasizes the superior potency of alpha particles, which are significantly more effective than traditional beta particles, enabling the induction of double-strand DNA breaks in cancer cells and reducing the likelihood of acquired resistance.

The company employs a unique theranostic strategy, integrating imaging tools to monitor the delivery and effectiveness of their radiopharmaceuticals within the body. This allows for precise targeting and verification of tumor engagement, enhancing the potential for successful treatment outcomes. Aktis Oncology also prioritizes the logistics of radiopharmaceutical delivery, ensuring timely access to their therapies for patients. By focusing on both efficacy and safety, Aktis is positioned to transform the landscape of cancer care, offering new hope for patients with solid tumors at various stages of disease.

United States

Aktis Oncology is a biotechnology company dedicated to realizing the curative power of alpha radiopharmaceuticals for the mainstream of cancer care.

Aktis Oncology

Company Details